This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Leukotrienes

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The lipoxygenase enzymes are based in the cytosol of the lung, platelets and leukocytes. They convert arachidonic acid into hydroperoxy derivatives termed leukotrienes. The triggers for production are varied e.g. antigen binding in association with IgE in mast cells, activation of platelets. Leukotrienes are produced only when required.

The steps in production include:

  • conversion of arachidonic acid to 5-hydroperoxyeicosatetraenoic acid, 5-HPETE, by the enzyme 5-lipoxygenase
  • conversion of 5-HPETE to hydroxyeicosatetraenoic acid, HETE, by glutathione peroxidase
  • or, coversion of 5-HPETE to leukotriene A4, LTA4, by the action of dehydrase enzymes

LTA4 then forms the basis for the production of further leukotrienes:

  • leukotriene B4, LTB4, is formed by the action of a hydrolase predominantly in neutrophils
  • leukotriene C4, LTC4, is formed by the action of a glutathione transferse enzyme in a range of cells

LTC4 may be futher enzymatically converted to leukotrienes D4 and E4, LTD4 and LTE4 respectively, by amino acid substitution.


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.